

STAND. COM. REP. NO.

216

Honolulu, Hawaii

February 10, 2017

RE: H.B. No. 1132

H.D. 1

Honorable Joseph M. Souki
Speaker, House of Representatives
Twenty-Ninth State Legislature
Regular Session of 2017
State of Hawaii

Sir:

Your Committee on Health, to which was referred H.B. No. 1132
entitled:

"A BILL FOR AN ACT RELATING TO THE UNIFORM CONTROLLED
SUBSTANCES ACT,"

begs leave to report as follows:

The purpose of this measure is to update the State's Uniform
Controlled Substance Act to authorize the prescription or
dispensing of drugs including buprenorphine and naloxone to
patients for purposes of detoxification treatment and maintenance
treatment by properly authorized practitioners, consistent with
federal law. This measure also requires the deposit of all fines
collected for violation of the Uniform Controlled Substance Act
into the Controlled Substance Registration Revolving Fund,
consistent with that Fund's purpose.

Your Committee received testimony in support of this measure
from Walgreens Co. and an individual. Your Committee received
comments on this measure from the Department of Public Safety,
Department of Health, Department of the Attorney General, and
Hawaii Substance Abuse Coalition.

Your Committee has amended this measure by:

- (1) Changing its effective date to July 1, 2090, to
encourage further discussion; and

HB1132 HD1 HSCR HLT HMS 2017-2040



- (2) Making technical, nonsubstantive amendments for the purpose of clarity and consistency.

As affirmed by the record of votes of the members of your Committee on Health that is attached to this report, your Committee is in accord with the intent and purpose of H.B. No. 1132, as amended herein, and recommends that it pass Second Reading in the form attached hereto as H.B. No. 1132, H.D. 1, and be referred to your Committee on Judiciary.

Respectfully submitted on
behalf of the members of the
Committee on Health,

Debra A. Belatti

DELLA AU BELATTI, Chair



